Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. uri icon

authors

  • Connor, Matthew P
  • Matthews, Andrew H
  • Shannon R. McCurdy, MD
  • Perl, Alexander E
  • Porter, David L
  • Zeringue, Arlene
  • Oved, Joseph H
  • Olson, Timothy S
  • Pratz, Keith W
  • Babushok, Daria V
  • Prathapa, Neeharika
  • Frey, Noelle V
  • Gill, Saar I
  • Hexner, Elizabeth O
  • Bruno, Ximena Jordan
  • Lai, Catherine E
  • Loren, Alison W
  • Luger, Selina M

publication date

  • August 1, 2024